Ustekinumab
- Generic Name
- Ustekinumab
- Brand Names
- Stelara, Pyzchiva, Uzpruvo, Wezenla, Steqeyma, Otulfi, Fymskina, Eksunbi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 815610-63-0
- Unique Ingredient Identifier
- FU77B4U5Z0
- Background
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMAR...
- Indication
Ustekinumab is indicated for the management of moderate to severe plaque psoriasis in patients 6 years of age and older who are candidates for phototherapy or systemic therapy. In adult patients, it is also indicated for the management of active psoriatic arthritis (PsA) alone or in combination with methotrexate, moderately to severely active Crohn’s disease...
- Associated Conditions
- Severe Plaque psoriasis, Ulcerative Colitis, Active Severe, Active Psoriatic arthritis, Moderate Plaque psoriasis, Moderate Ulcerative colitis, Moderate, active Crohn´s Disease, Severe, active Crohn´s Disease
- Associated Therapies
- -
A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT01276847
Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis
- Conditions
- Interventions
- First Posted Date
- 2010-03-23
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Innovaderm Research Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT01091051
- Locations
- 🇨🇦
Lynderm Research, Markham, Ontario, Canada
🇨🇦Kirk Barber Research, Calgary, Alberta, Canada
🇨🇦Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada
Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis
- Conditions
- First Posted Date
- 2010-03-19
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT01090063
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01081704
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 490
- Registration Number
- NCT01059773
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT01008995
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT00955279
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT00320216
A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Centocor Research & Development, Inc.
- Target Recruit Count
- 766
- Registration Number
- NCT00267969
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.